Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Papillomavirus Infections 1Hepatitis C, Chronic 1Fibrosis 1Condylomata Acuminata 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Viusid × Clear all
NCT03584308 2019-05-22

Efficacy of VIUSIDĀ® Plus GLIZIGENĀ® in Patients With Papilloma Virus Esophageal

Catalysis SL

Phase 2 Completed
110 enrolled

Papillomavirus Infections

NCT01111344 2012-05-08

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Catalysis SL

Phase 3 Completed
76 enrolled

Condylomata Acuminata

NCT00502086 2011-02-11

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Catalysis SL

Phase 3 Completed
100 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon ⚔